Teriflunomide evaluated in pediatric patients with relapsing MS

Although the TERIKIDS study failed to meet its primary endpoint, pediatric patients with multiple sclerosis (MS) had similar benefits from therapy to adult patients, researchers reported at the EAN Virtual Congress. As Dr Tanuja Chitnis from the Massachusetts General Hospital for Children, Boston, USA, explained, high crossover from the placebo group to active therapy biased the results against treatment efficacy.

Vuoi saperne di più?

Accedi o registrati per accedere a tutti i contenuti di Neurodiem.

Hai già un account? Accedi

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.